Norway’s PCI Biotech is initiating a pre-clinical research collaboration with American biotechnology company RXi Pharmaceuticals.
The purpose of the pre-clinical research collaboration “is to utilize the companies’ complementary scientific platforms to explore potential synergies,” according to information from PCI Biotech. The partnership will evaluate technology compatibility based on in vitro and in vivo studies. Each company will cover its own research costs.
The companies plan to review research results from the collaboration and then explore the potential for working more closely together.
Both companies will retain exclusive ownership rights to existing registered intellectual property. However, any inventions arising from the collaboration will be jointly owned by the companies, a company statement notes.
PCI Biotech is a biopharmaceutical company focused on cancer research. The company is developing therapeutic products based on its proprietary photochemical internalization (PCI) technology.
Source: PCI Biotech